secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0001104659-22-070604
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance appoints Wendy Dixon to board; retains chairman Dukes after failed re-election
--------------------------------------------------------------------------------

- Appointed Wendy Dixon, Ph.D. to board effective June 10, 2022; granted RSU valued at $425,000 (8.30/sh).
- Chairman Iain Dukes received more withheld votes than for votes at annual meeting; board rejected his conditional resignation.
- Dukes' non-independence due to prior consulting agreement expires Dec 2022; board cited valuable contributions.
- Stockholders approved increase in 2018 Equity Plan from 14M to 20.7M shares (6.7M new shares).
- Other proposals: executive compensation (advisory) and auditor ratification passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465922070604/0001104659-22-070604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465922070604/tm2218321d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-070604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer